(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of -38.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Entrada Therapeutics's revenue in 2024 is $129,013,000.On average, 3 Wall Street analysts forecast TRDA's revenue for 2024 to be $2,983,979,553, with the lowest TRDA revenue forecast at $1,895,774,231, and the highest TRDA revenue forecast at $4,368,143,390. On average, 2 Wall Street analysts forecast TRDA's revenue for 2025 to be $1,199,895,388, with the lowest TRDA revenue forecast at $504,016,545, and the highest TRDA revenue forecast at $1,895,774,231.
In 2026, TRDA is forecast to generate $1,367,900,903 in revenue, with the lowest revenue forecast at $840,027,575 and the highest revenue forecast at $1,895,774,231.